- Home
- BEATW vs POAI Comparison
BEATW vs POAI Comparison
Compare BEATW & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- POAI
- Stock Information
- Founded
- BEATW 2015
- POAI 2002
- Country
- BEATW United States
- POAI United States
- Employees
- BEATW 20
- POAI N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- POAI Industrial Specialties
- Sector
- BEATW Technology
- POAI Health Care
- Exchange
- BEATW Nasdaq
- POAI Nasdaq
- Market Cap
- BEATW N/A
- POAI N/A
- IPO Year
- BEATW N/A
- POAI N/A
- Fundamental
- Price
- BEATW $0.51
- POAI $1.40
- Analyst Decision
- BEATW
- POAI Hold
- Analyst Count
- BEATW 0
- POAI 1
- Target Price
- BEATW N/A
- POAI N/A
- AVG Volume (30 Days)
- BEATW 4.7K
- POAI 8.1M
- Earning Date
- BEATW 03-14-2025
- POAI 05-13-2025
- Dividend Yield
- BEATW N/A
- POAI N/A
- EPS Growth
- BEATW N/A
- POAI N/A
- EPS
- BEATW N/A
- POAI N/A
- Revenue
- BEATW N/A
- POAI $1,623,817.00
- Revenue This Year
- BEATW N/A
- POAI $486.27
- Revenue Next Year
- BEATW N/A
- POAI $65.50
- P/E Ratio
- BEATW N/A
- POAI N/A
- Revenue Growth
- BEATW N/A
- POAI N/A
- 52 Week Low
- BEATW $0.50
- POAI $0.55
- 52 Week High
- BEATW $0.62
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- POAI 52.81
- Support Level
- BEATW N/A
- POAI $1.26
- Resistance Level
- BEATW N/A
- POAI $1.58
- Average True Range (ATR)
- BEATW 0.00
- POAI 0.20
- MACD
- BEATW 0.00
- POAI 0.03
- Stochastic Oscillator
- BEATW 0.00
- POAI 22.58
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.